Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New drug 'benefits heart failure patients'

  • Comment

Treatment for heart failure patients could soon include a new type of drug, research has indicated.

Myosin activators help the heart beat more easily by targeting specific proteins to make its muscles contract for longer.

Instead of causing the heart to beat more often, the drugs increase the amount of blood pumped out each time.

The first of these drugs, omecamtiv mecarbil, has been tested by researchers in the UK.

Their findings, published in The Lancet, reveal that the drug significantly improved heart function in 45 patients suffering from heart failure.

Professor John Cleland from the University of Hull, who led the study, said: “The trial proves that the drug can be given safely to patients suffering from heart failure and shows that, at the correct doses and blood plasma concentrations, it can improve heart function and make the heart contract more effectively.”

British Heart Foundation senior cardiac nurse Natasha Stewart said: “Although there were minimal adverse effects identified in these initial trials, only a small number of participants over a short period of time were involved.”

Heart failure affects more than 750,000 people across the UK.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs